BI 201335 low dose

DRUG2 trials

Sponsors

Boehringer Ingelheim

Conditions

HealthyHepatitis C

Phase 1

Assessment of the Effect of BI 201335 on the QT Interval in Healthy Female and Male Subjects

CompletedNCT02182310

Boehringer IngelheimHealthy

Start: 2008-06-30Updated: 2014-07-18

Phase 3

Japanese Pegylated Interferon (PegIFN) Alfa-2b/Ribavirin (RBV) Combination Trial

CompletedNCT01579474

Boehringer IngelheimHepatitis C

Start: 2012-04-30End: 2013-12-31Updated: 2015-08-03

Related Papers

Safety and efficacy of faldaprevir in combination with pegylated interferon α‐2b and ribavirin in Japanese patients with genotype‐1 chronic hepatitis C virus infection

Hepatology Research2016-05-06